- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Wearable Device, Duchenne Video Assessment (DVA)
- Device · Other
- Lead sponsor
- Solid Biosciences Inc.
- Industry
- Eligibility
- 4 Years to 12 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 10,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Huntington Disease
- Interventions
- Not listed
- Lead sponsor
- Huntington Study Group
- Network
- Eligibility
- 26 Years to 55 Years
- Enrollment
- 1,001 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2009
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
- Conditions
- Phenylketonurias
- Interventions
- sapropterin dihydrochloride
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Oakland, California • Sacramento, California + 11 more
- Conditions
- Urea Cycle Disorder
- Interventions
- Diagnostic Ultrasound
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency
- Interventions
- Ultrase® MT12
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
- Conditions
- Generalized Lipodystrophy
- Interventions
- mibavademab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Ann Arbor, Michigan
- Conditions
- Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
- Interventions
- Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Placental Transfusion
- Interventions
- Short Delay Cord Clamping, Extended Delay Cord Clamping
- Procedure
- Lead sponsor
- Anup Katheria, M.D.
- Other
- Eligibility
- 37 Weeks to 42 Weeks
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Atopic Dermatitis
- Interventions
- Tezepelumab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
- Conditions
- Cystic Fibrosis
- Interventions
- Sildenafil 40mg oral capsule, Placebo Oral capsule
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 9 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Augusta, Georgia
- Conditions
- Hypovolemia, Craniosynostoses
- Interventions
- CardioQ-EDM and CipherOx-CRI
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 3 Months to 2 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Charcot-Marie-Tooth Disease, Healthy
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Luminex Corporation
- Industry
- Eligibility
- 1 Day to 7 Days
- Enrollment
- 7,462 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Albany, New York • Nashville, Tennessee • Taylorsville, Utah
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, double-unit umbilical cord blood transplantation, total-body irradiation, tacrolimus, peripheral blood stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Hemophilia A
- Interventions
- SPK-8011QQ
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Orange, California • San Francisco, California • Vallejo, California + 3 more
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
- Conditions
- Port Wine Stain
- Interventions
- Imiquimod, Placebo
- Drug · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- Not listed
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Hereditary Angioedema
- Interventions
- Navenibart
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa
- Interventions
- AZLI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 12 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more
- Conditions
- Cerebral Palsy, Spina Bifida
- Interventions
- Virtual Peer Health Coaching
- Behavioral
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Gout
- Interventions
- Febuxostat XR
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Wilson Disease
- Interventions
- NCC-Sp Assay
- Diagnostic Test
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Sacramento, California • New Haven, Connecticut • Miami, Florida + 6 more
- Conditions
- Hemophilia A, Hemophilia B, Vitamin D Deficiency
- Interventions
- Vitamin D and calcium
- Dietary Supplement
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 2 Years to 21 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
- Interventions
- Magnetic Resonance High Intensity Focused Ultrasound
- Device
- Lead sponsor
- AeRang Kim
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Cincinnati, Ohio